Periodontitis is associated with dental plaque accumulation, which produces gingival inflammation and periodontal tissue destruction. The major oral pathogens that promote chronic inflammation in periodontal cells are Gram-negative bacteria including Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Bacteroides forsythus. These bacteria trigger periodontal host cells to release inflammatory mediators including cytokines such as interleukin 1b (IL-1b), tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), matrix metalloproteinases (MMPs), chemokines, and prostaglandins. 1, 2) The initial synthesis of these mediators combats the noxious effects of the pathogens, however their excess expression promotes chronic inflammatory responses. Among MMP groups, MMP-9 (a 92-kDa gelatinase B) is thought to be a key enzyme for degrading type IV collagen and specifically regulating basement membrane remodeling during periodontitis progression. In patients with chronic periodontitis, MMP-9 expression in gingival tissue, dental plaque, saliva and gingival crevicular fluid is significantly elevated, indicating that MMP-9 primarily participates in periodontal tissue destruction. 3) P. gingivalis promotes the activation of several kinases that are known to participate in inflammatory pathways including extracellular signal-related kinase 1/2 (ERK1/2) and p38 in periodontal host cells. [4] [5] [6] Therefore, it is likely that the activation of these mitogen activated-protein kinase (MAPK) pathways is a critical mechanism by which P. gingivalis causes chronic inflammation and contributes to periodontal disease. The three major groups of MAPKs that regulate gene expression are ERK1/2, p38, and c-Jun N-terminal kinase (JNK). Mitogens and growth factors primarily activate ERK1/2. In contrast, JNK and p38 are activated by proinflammatory cytokines such as IL-1b and TNF-a, and cell stress-inducing factors such as heat shock, ultraviolet radiation, and oxygen radicals. Each of the three MAPK groups activates different transcriptional factors including terminal complex factors/Elk-1, cyclic AMP-responsive element binding (CREB), c-Jun, activating transcription factor-2 (ATF-2), and myocyte-specific enhancer factor2 (MEF2) which in turn activate the expression of the transcription factors genes cFos and c-Jun. 7) Phosphorylated c-Fos forms nuclear heterodimers, mainly with c-Jun family transcription factors, and stimulates the expression of genes regulated by the activator protein-1 (AP-1) promoter element. 8) Together these transcription factors control the activation of gene promoters containing AP-1, nuclear factor-kappa B (NF-kB), and C/EBP (ccAAT enhances binding protein) elements to control the expression of target genes resulting inflammatory responses including MMPs. 9) A number of strategies have been designed to block the excess production of MMPs by periodontal host cells to treat periodontitis. Inhibition of MMPs via blocking enzymatic activity offers a straightforward therapeutic target in periodontal disease therapy. Several synthetic MMP inhibitors like tetracyclines, antracyclines, and synthetic peptides have been investigated, however, their efficacy in the clinical models is Porphyromonas gingivalis, a type of Gram-negative periodontopathogen, causes periodontal disease by activating intracellular signaling pathways that produce excessive inflammatory responses such as matrix metalloproteinases (MMPs). Recently, we reported that panduratin A, a chalcone compound isolated from Kaempferia pandurata ROXB., caused the decreased levels of MMP-9 secretion, protein, and gene expression in human oral epidermoid KB cells exposed to P. gingivalis supernatant. In this study, we clarified if mitogen-activated protein kinase (MAPK) signaling mediated MMP-9 expression by examining the effect of specific MAPK inhibitors, i.e. U0126, SB203580, and SP600125, on P. gingivalis supernatant-stimulated MMP-9 expression in KB cells. We next elucidated the molecular mechanism by which panduratin A attenuated signaling pathways involved in MMP-9 expression by performing gelatin zymography, Western blotting, reverse transcription-polymerase chain reaction, and promoter assays. still doubtful. 10, 11) Natural products from medicinal plants such as black rice anthocyanins, green tea cathecin, and cranberry constituents have received considerable attention as therapeutic agents in managing periodontitis because of their safety and effectiveness as MMP inhibitors. [12] [13] [14] Other strategy to inhibit MMP expression involves targeting the signaling pathways that mediate MMP induction. The use of MAPK inhibitors is the most promising strategy because these drugs reduce both the synthesis of pro-inflammatory cytokines and their subsequent inflammatory signaling. 15) Additionally, most MAPK inhibitors produced by chemical synthesis are small molecules that can be administrated orally. To date, flavonoids such as luteolin, quercetin, genistein, and quercetagetin have been reported to block activation of ERK1/2, p38, Akt, and NF-kB translocation in P. gingivalis lipopolysaccharide (LPS)-induced human gingival fibroblasts. 16, 17) Kaempferia pandurata ROXB. (Zingiberaceae), known as temu kunci in Indonesia and krachai in Thailand, has been traditionally used in the culinary arts and folk medicine for the treatment of dental caries, colic, fungal infections, dry cough, rheumatism, and muscular pain. 18) Rhizomes of K. pandurata contain pinostrobin, cardamonin, boesenbergin, 5,7-dimethoxyflavone, 1,8-cineole, panduratin A, and other compounds. 19) Of these, panduratin A is a natural chalcone compound with a molecular weight of 406 that has been found to possess anti-carcinogenic, anti-inflammatory, anticancer, proapoptotic, and anti-oxidant properties. [20] [21] [22] [23] In a previous study, we found that panduratin A inhibited MMP-9 expression by P. gingivalis supernatant-stimulated human oral epidermoid KB cells. 24) However, it is currently unknown if panduratin A can directly affect signaling pathways involved in regulation of MMP-9 expression. Periodontal disease is promoted by oral bacterial products, thus we used P. gingivalis supernatant to stimulate the activation of MAPK signaling in KB host cells as a model for periodontal disease. Using this model, we assessed the ability of panduratin A to inhibit MAPK signaling involved in regulation of MMP-9 expression in KB cells exposed to P. gingivalis supernatant.
MATERIALS AND METHODS

Materials and Reagents
The dried rhizomes of Kaempferia pandurata ROXB. were collected in Jakarta, Indonesia, and identified by Dr. Nam-In Baek, Department of Oriental Medicinal Materials and Processing, Kyunghee University (Yongin, Korea). A voucher specimen (H082) was deposited in the Department of Biotechnology, Yonsei University (Seoul, Korea). Panduratin A (Fig. 1 ) isolated from K. pandurata ROXB. 22, 25) was dissolved in 100% (v/v) dimethyl sulfoxide (DMSO) and the final concentration of DMSO in culture cell was 0.1% (v/v). P. gingivalis ATCC 33277 was purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). U0126 (MEK1/2 inhibitor) was obtained from Cell Signaling Technology (Beverly, MA, U.S.A.). SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor) were purchased from Calbiochem (San Diego, CA, U.S.A.). All MAPK inhibitors were first dissolved in DMSO and then diluted with the culture medium with the total concentration of 0.1% (v/v). The final concentrations of U0126, SB203580, and SP600125 used in this study were 20 mM, respectively. The primary anti-rabbit polyclonal antibodies against MMP-9, ERK1/2, p38, JNK, Elk1, c-Jun, c-Fos, and anti-mouse monoclonal antibodies to p-ERK1/2, p-p38, p-JNK, p-Elk1, p-c-Jun were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-mouse monoclonal a-tubulin were obtained from Calbiochem (San Diego, CA, U.S.A.). The secondary antibody peroxidase-conjugated anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG were obtained from Cell Signaling Technology (Beverly, MA, U.S.A.) and Calbiochem (San Diego, CA, U.S.A.). The AP-1 luciferase reporter plasmid was a gift from Dr. Baek-Il Kim, Department of Preventive Dentistry and Public Oral Health, Yonsei University (Seoul, Korea).
Cell Culture and Cell Viability KB cells (human oral epidermoid cell line, ATCC CCL-17) were obtained from the American Type Culture Collection (Manassas, VA, U.S.A.). The cells were cultured in a 5% CO 2 atmosphere at 37°C in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Grand Island, NY, U.S.A.) supplemented with 100 U/ml of penicillin A, 100 U/ml of streptomycin, and 10% heatinactivated fetal bovine serum (FBS). The cells were seeded at a concentration of 2ϫ10 5 cells/ml per 75-cm 2 flask (SPL, Seoul, Korea) and cultured for 24 h. As previously described, 24 ) the effects of P. gingivalis supernatant and panduratin A on cell viability were evaluated with an MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO, U.S.A.) colorimetric assay.
Bacterial Supernatant and Sample Treatment P. gingivalis supernatant was prepared as described by Chang et al. 26) with a slight modification. Cells were seeded at a concentration of 2ϫ10 5 cells/ml in 6-well plates and cultured for 24 h in DMEM-FBS. After washing with Dulbecco's phosphate-buffered saline (DPBS), the cells were incubated in serum free-DMEM without P. gingivalis supernatant (negative control group), with 10% P. gingivalis supernatant (positive control group), or with 10% P. gingivalis supernatant plus various concentrations of panduratin A (treatment groups) for 48 h. Cell lysates and conditioned media were collected for these experiments.
Gelatin Zymography MMP-9 secretion in the conditioned media was measured by gelatin zymography. Briefly, cells were treated with P. gingivalis supernatant plus MAPK inhibitors (U0126, SB203580, and SP600125) for 48 h. The conditioned media were collected and subjected to electrophoresis with 10% sodium dodecyl sulfate (SDS) polyacrylamide gels containing 0.2% gelatin as previously described. 24) Western Blotting To determine MMP-9 protein expression, the conditioned media from cells treated with P. gingivalis supernatant plus MAPK inhibitors were concentrated with Fast-Con Protein Concentration kit (Corebio, Belmont, CA, U.S.A.) and subjected to Western blotting. To determine the expression of MAPK phosphorylation and transcription factor expression, cellular lysates from the negative control, positive control, and treatment group (panduratin A) were prepared and assayed by Western blot analysis. Proteins (50 mg) were resolved by 10% SDS-PAGE and transferred to nitrocellulose transfer membranes. The membranes were blocked with 5% skim milk for 1 h at room temperature and then probed with the primary anti-rabbit polyclonal antibodies to MMP-9 and c-Fos, and anti-mouse monoclonal antibodies against p-ERK1/2, p-p38, p-JNK, p-Elk1, p-c-Jun at a 1 : 1000 dilution overnight at 4°C. After three washes, the blots were subsequently incubated with the secondary antibody peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG at a 1 : 4000 dilution for 2 h at room temperature. The blots were stained with SuperSignal West Femto Maximum sensitivity substrate (Thermo Scientific, Rockford, IL, U.S.A.) and visualized using a LAS 3000 Bio Imaging Analysis System (Lab Science, Fuji Film, Tokyo, Japan). Equal loading of blots was demonstrated by stripping blots and reprobing with anti-rabbit polyclonal antibodies for ERK1/2, p38, JNK, Elk1, c-Jun, and anti-mouse monoclonal a-tubulin.
Reverse Transcription-Polymerase Chain Reaction (PCR) MMP-9 mRNA in the cell lysates was determined by RT-PCR. Briefly, cells were treated with P. gingivalis supernatant plus MAPK inhibitors (U0126, SB203580, and SP600125) for 48 h. Total RNA from cells was extracted as previously described.
24)
Promoter Assay Cells were seeded at a concentration of 1ϫ10 6 cells/ml in 6-well plates and cultured in DMEM-FBS for 6 h at 37°C in a 5% CO 2 atmosphere prior to the experiments. For transient transfection, a 2.0 mg AP-1 plasmid was mixed with Lipofectamine reagent (Invitrogen, Carlsbad, CA, U.S.A.) in 100 ml of serum-free DMEM. A 0.25 mg of bgalactosidase plasmid was used as the internal control. Cells were incubated for 5 h. For luciferase assays, cells were treated with various doses of panduratin A (5, 12.5, 25 mM) or MAPK inhibitors (U0126, SB203580, and SP600125) for 48 h. Cell lysates were collected and luciferase activity was tested using a luciferase assay system (Promega, Madison, WI, U.S.A.) according to the manufacturer's instructions. Firefly luciferase activities were standardized for b-galactosidase activity.
Statistical Analysis Triplicate experiments were performed throughout this study. All data are presented as the meanϮstandard deviation (S.D.). The significance of differences between control and treated groups were statistically analyzed by the paired Student's t-test ( * pϽ0.05, * * pϽ 0.01).
RESULTS
P. gingivalis Supernatant Stimulated MMP-9 Expression, AP-1 Activity, MAPK Activation, and Transcription Factor Expression in KB Cells The effect of P. gingivalis supernatant on MMP-9 induction in KB cells was examined by performing gelatin zymography, Western blotting, and RT-PCR. As determined by gelatin zymography, the main gelatinolytic band with a molecular weight of 92 kDa secreted from P. gingivalis supernatant-stimulated KB cells indicated the presence of MMP-9. In KB cells, P. gingivalis supernatant (10%) stimulated the expression of MMP-9 secretion and protein in comparison with unstimulated cells (Fig. 2A) . MMP-9 mRNA of KB cells also increased after treating with P. gingivalis supernatant (Fig. 2A) .
AP-1 is a regulatory element in the promoter regions of human MMP genes including MMP-9 gene. 27) In this study, Cells treated with P. gingivalis supernatant (10%) were cultured for 48 h. Untreated cells (without P. gingivalis supernatant) were used as controls. (A) For MMP-9 secretion, culture media were assayed by gelatin zymography. For MMP-9 protein, culture media were concentrated and analyzed by Western blotting using MMP-9 antibody. For MMP-9 mRNA, total RNA was extracted from cell lysates and MMP-9 mRNA was determined by RT-PCR. GAPDH mRNA was used as an internal control. KB cells were transfected with AP-1 luciferase reporter plasmids and treated with P. gingivalis supernatant. Our results showed that P. gingivalis supernatant was able to produce about 3.4-fold increase in the activation of AP-1 element, compared to unstimulated cells (pϽ0.01; Fig. 2B ).
Using Western blot assays, we investigated whether P. gingivalis supernatant interfered with MAPK phosphorylation or transcription factor expression in KB cells. As shown in Figs. 2C and D, treatment with P. gingivalis supernatant upregulated MAPK phosphorylation (ERK1/2, p38, and JNK) and the expression of transcription factors (Elk1, c-Jun, and c-Fos) compared to the total levels of MAPKs and transcription factors in unstimulated cells.
JNK and AP-1 Signaling Mediated P. gingivalis Supernatant-Stimulated MMP-9 Expression in KB Cells
Using specific MAPK inhibitors, i.e. U0126 (MEK1/2 inhibitor), SB203580 (p38 inhibitor), and SP600125 (JNK inhibitor), we identified whether MAPK signaling mediated MMP-9 expression in KB cells exposed to P. gingivalis supernatant. Inhibitors of MEK1/2 and p38 caused the decreased levels in P. gingivalis supernatant-stimulated MMP-9 secretion, protein, and gene expression (Fig. 3A) . Interestingly, a JNK inhibitor (SP600125) was able to completely block MMP-9 secretion and protein, and strongly attenuate MMP-9 gene expression (Fig. 3A) .
To examine if MAPK signaling participated in P. gingivalis supernatant-stimulated MMP-9 gene expression was mediated through AP-1 element, KB cells were transfected with AP-1 luciferase reporter plasmids and treated with P. gingivalis supernatant in the absence or presence of MAPK inhibitors. Among three specific MAPK inhibitors, SP600125 (a JNK inhibitor) was found to significantly abolish Ͼ65% of AP-1 activity in P. gingivalis supernatant-stimulated KB cells, and it had no effect on AP-1 basal activity in unstimulated cells (pϽ0.01; Fig. 3B ).
We also tested the effect of MAPK inhibitors on MAPK phosphorylation induced by P. gingivalis supernatant in KB cell by Western blotting. As expected, treatment with MAPK inhibitors (U0126, SB203580, and SP600125) at 20 mM significantly suppressed P. gingivalis supernatant-stimulated activation of ERK1/2, p38, and JNK phosphorylation (Fig. 3C) .
Panduratin A Inhibited P. gingivalis Supernatant-Stimulated AP-1 Activity, MAPK Activation, and Transcription Factor Expression in KB Cells As previously reported, 24) panduratin A significantly attenuated MMP-9 secretion, protein, and gene in KB cells exposed to P. gingivalis supernatant. In the present study, we determined whether the downstream effect of panduratin A on MMP-9 expression was mediated through AP-1 element, which is responsible for transcription of MMP-9 gene expression. As shown in Fig. 4A , cells treated with P. gingivalis supernatant in the presence of panduratin A demonstrated the reduced levels of AP-1 activity in the dose-dependent manner. Panduratin A at 25 mM significantly suppressed Ͼ80% of AP-1 activity (pϽ0.01).
We further assessed the effect of panduratin A on P. gingivalis signaling pathway of KB cells through regulating MAPK phosphorylation. Panduratin A at various doses inhibited P. gingivalis supernatant-stimulated ERK1/2, p38, and JNK phosphorylation (Fig. 4B ) in comparison to untreated control cells without altering the total levels of ERK1/2, p38, and JNK. Similar results were also obtained from specific MAPK inhibitors (Fig. 3C) . Panduratin A at 25 mM totally blocked the most phosphorylation of ERK1/2 and JNK. In contrast, panduratin A exerted a lesser in- Cells treated with MAPK inhibitors (U0126, SB203580, and SP600125) at 20 mM and P. gingivalis supernatants (10%) were cultured for 48 h. Untreated cells (without MAPK inhibitors and P. gingivalis supernatant) were used as controls. (A) For MMP-9 secretion, culture media were assayed by gelatin zymography. For MMP-9 protein, culture media were concentrated and analyzed by Western blotting using MMP-9 antibody. For MMP-9 mRNA, total RNA was extracted from cell lysates and MMP-9 mRNA was determined by RT-PCR. GAPDH mRNA was used as an internal control. (B) For AP-1 activity, after 5 h transfection, cells treated with MAPK inhibitors and P. gingivalis supernatant were cultured for 48 h. The luciferase activity of AP-1 reporter plasmid-transfected cells divided the b-galactosidase activity of b-galactosidase plasmid-transfected cells represents the relative luciferase unit (RLU) for AP-1 activity of each experiment. Data are shown as meanϮS.D. from triplicate separate experiments ( * pϽ0.05, * * pϽ0.01 compared with the control). (C) For MAPK activation, cell lysates were analyzed by Western blot using anti-p-ERK1/2, p-p38 and p-JNK antibodies. Membranes were stripped and reprobed using an antibody against each protein as a control for equal loading.
hibitory effect on p38 phosphorylation in comparison to ERK1/2 and JNK phosphorylation. Panduratin A was also tested for its effect on the expression levels of MAPK transcription factors, such as phosphorylated Elk1, phosphorylated c-Jun, and c-Fos, in P. gingivalis supernatant-stimulated KB cells. Panduratin A at 25 mM resulted in similar inhibitory effects on Elk1 phosphorylation, c-Jun phosphorylation, and c-Fos expression (Fig. 4C) in comparison with the untreated control cells without altering the total levels of Elk1, c-Jun, and c-Fos.
DISCUSSION
Periodontal disease is caused by periodontopathogen infections that affect the supporting tissues of the teeth, leading to progressive destruction of connective tissue attachments and alveolar bone. P. gingivalis is known as the primary pathogen responsible for inflammatory stimuli in the initiation and progression of periodontitis. P. gingivalis has virulence factors like gingipains, lipopolysaccharides, and fimbriae, and activates several MMPs including MMP-9 in various periodontal cell lines. 2, 28, 29) Our results confirm that P. gingivalis supernatant up-regulated MMP-9 secretion, protein, and gene expression ( Fig. 2A) , suggesting that P. gingivalis supernatant may be involved in the progress of periodontitis through the production of MMP-9 in KB cells. It has been reported that gingipains and lipopolysaccharides of P. gingivalis products contribute to an increased level of MMP-9 secretion from human oral epithelial cells. 28, 29) AP-1 and NF-kB transcription factor elements are located in the human MMP-9 promoter region. 27 ) P. gingivalis supernatant was found to alter the activation of AP-1 element in KB cells (Fig. 2B) , and interestingly, its ability to induce AP-1 activity was stronger than that of NF-kB activity (data not shown). These results imply that AP-1 element mainly controls the transcription of MMP-9 gene expression stimulated by P. gingivalis supernatant in KB cells. P. gingivalis supernatant also promoted and triggered the activation of MAPKs including ERK1/2, p38, and JNK in KB cells (Fig. 2C) , that led to a significant production of inflammatory mediators including MMP-9. Thus, it is conceivable that MMP-9 gene expression stimulated by P. gingivalis supernatant in KB cells requires AP-1 element at transcriptional level and is activated via MAPK signaling.
The MAPK signaling pathways have an important role in regulating several MMP gene expression including MMP-9 gene, and activating major transcription factors like AP-1 and NF-kB. To date, only a few studies observed that MAPK and PI3K (phosphatidylinositol-3 kinase) signaling pathways were involved in regulation of MMP-9 expression in human periodontal cell lines. 26, 30) However, the mechanisms and signaling pathways involved in the MMP-9 expression in KB cells exposed to P. gingivalis supernatant still remain unclear. As P. gingivalis supernatant activates three MAPK members (ERK1/2, p38, and JNK) in response to KB cells (Fig. 2C) , these signaling pathways are thought to be important signaling mechanisms associated with the periodontal inflammation. In this study, we used spesific MAPK inhibitors, i.e. U0126, SB203580, and SP600125, to investigate the involvement of MAPK signaling and AP-1 element in P. gingivalis supernatant-stimulated MMP-9 expression in KB cells. Our results clearly demonstrated that SP600125 (a JNK inhibitor) significantly inhibited the expression of MMP-9 protein and mRNA (Fig. 3A) , suggesting that JNK signaling is primarily involved in regulation of MMP-9 gene expression in P. gingivalis supernatant-stimulated KB cells. SP600125 also strongly abolished AP-1 activity (Fig. 3B) . As AP-1 is responsible for controlling the expression of MMP-9 gene, 27) it is possible that AP-1, regulated by JNK signaling, may cooperate in activation of MMP-9 gene expression in P. gingivalis supernatant-stimulated KB cells.
Inhibition of MAPK phosphorylation by naturally-occurring agents presents an attractive strategy to block the excess production of MMPs for periodontitis treatment. Panduratin A, a chalcone compound isolated from the rhizome of K. pandurata ROXB., has potent inhibitory activities against multi-species oral biofilm and MMP-9 expression in P. gingivalis supernatant-stimulated KB cell in vitro. 24, 31) Therefore, it is thought that panduratin A could be applied for treatment of periodontal disease. In the present study, we observed that panduratin A dose-dependently suppressed the activation of AP-1 element upon stimulation with P. gingivalis supernatant in KB cells (Fig. 4A) . Meanwhile, our previous reports showed that panduratin A caused the decreased levels of MMP-9 secretion, protein, and gene in KB cells in response to P. gingivalis supernatant. 24) Panduratin A at 25 mM decreased Ͼ50% MMP-9 gene expression in P. gingivalis supernatant-stimulated KB cells. 24) These results imply that panduratin A blocks P. gingivalis supernatant-stimulated MMP-9 gene expression by partially decreasing AP-1 activity in KB cells. Furthermore, our findings exhibited that panduratin A completely abolished the expression of ERK1/2 and JNK phosphorylation (Fig. 4B) , indicating that panduratin A reduces P. gingivalis supernatant-stimulated MMP-9 gene expression by KB cells which is accompanied by inhibition of ERK1/2 and JNK signaling. This is also similar to the mechanisms of action of other naturally-occurring anti-inflammatory flavonoid compounds such as luteolin, quercetin, genistein, and quercetagetin which inhibit P. gingivalis LPS-stimulated MAPK activation in human gingival fibroblasts. 16, 17) Activation of MAPK phosphorylation by periodontopathogen products triggers activation of transcription factors, i.e. Elk1, c-Jun, and c-Fos, and transmits extracellular signals to the nucleus, which induce target gene expression. Elk1 phosphorylation is stimulated by ERK1/2, p38 and JNK activation. Meanwhile, c-Jun phosphorylation and c-Fos expression, which form AP-1 element for transcription of MMP-9 gene, are stimulated by JNK and ERK1/2 activation. Therefore, in KB cells, there is a link between activation of MAPKs and transcription factor members in response to P. gingivalis supernatant. Aggregatibacter actinomycetemcomitans LPS induces the expression of c-Fos and c-Jun in human gingival fibroblasts. 32) ERK1/2 and p38 are upstream of this c-Jun expression. Similarly, our P. gingivalis supernatant also increased expression of Elk1, c-Jun, and c-Fos transcription factors (Fig. 2D ). Kaminska reported that P. gingivalis products stimulated MAPK activation correlated with transcriptional induction. 15) After treatment with panduratin A at various doses, the expression of these transcriptional factors was partially attenuated (Fig. 4C) . These results suggest that panduratin A suppresses the induction of MMP-9 gene expression in response to P. gingivalis supernatant through the down-regulation of ERK1/2 and JNK, and partially attenuation of Elk1 or c-Jun phosphorylation and c-Fos expression.
Our findings provide evidence for the role of panduratin A on P. gingivalis supernatant-stimulated MMP-9 gene expression by suppressing P. gingivalis supernatant-stimulated AP-1 activation which may be mediated by blocking JNK phosphorylation in KB cells. In conclusion, the inhibition of JNK and AP-1 signaling may be one of the molecular mechanisms by which panduratin A inhibits regulation of MMP-9 expression in P. gingivalis supernatant-stimulated KB cells. These studies will be extended to in vivo tests using a gingival rat model to assess the utility of panduratin A for the treatment of periodontal disease.
